News

Bapineuzumab fails phase III
Enlarge image

BusinessIreland

Bapineuzumab fails phase III

26.07.2012 - Pfizer and Johnson & Johnson report that Bapineuzumab failed the first of four phase III trials.

The monoclonal antibody Bapineuzumab could not outperform a placebo in moderating symptoms of mild-to-moderate Alzheimer's disease. Expectations on an intravenous formulation of the drug to help a group of patients sharing the so called ApoE4 (apolipoprotein E epsilon 4) genotype could not be fulfilled. Pfizer did not release details of the study’s outcome, but a principal investigator in the trial, Reisa Sperling, told The New York Times that "there was absolutely no evidence at all of a clinical benefit of treatment on either of the primary measures." The antibody developed by the Irish company Elan and US company Pfizer is tested in a large-scale Alzheimer's Immunotherapy Program for its suitability for treating the most common form of dementia. Meanwhile Johnson & Johnson joined the team for a total of four clinical trials. 1100 patients participated in the trail, all of them carriers of the ApoE4 risk gene. It is possible that patients without this gene modification could gain more profit from the agent. A second study with this group will start in the following weeks, two others are still ongoing.

Bapineuzumab is the follow up agent of AN1792, a vaccine which also failed. AN1792 successfully stimulated the formation of antibodies against beta amyloid – a protein that can exert toxic effects in the brain and is believed to play a central role in the pathology of Alzheimer's disease – in animal studies. But in 2002, a phase II trial had to be stopped because of safety issues. Aseptic meningoencephalitis and leukoencephalopathy were diagnosed in 6 percent of the participants. Nevertheless, some hints were given that the vaccine achieved an effect. The same effects were expected for Bapineuzumab, of course without the negative consequences.

http://www.european-biotechnology-news.com/news/news/2012-03/bapineuzumab-fails-phase-iii.html

M&ASwitzerland

04.05.2015 Swiss crop chemical maker Syngenta AG is in talks with US company Monsanto discussing a possible merger, insiders say.

BiofuelsEU

30.04.2015 The European Parliament has given the go-ahead on a new law limiting the use of harmful crop-based biofuel in the transport sector. The decision marks a breakthrough in the EU’s approach to biofuels.

FinancingSwitzerlandUK

29.04.2015 Biopharma start-up CRISPR Therapeutics has raised US$64m to hurry the new CRISPR/Cas9 technology to the clinic.

FinancingBelgium

28.04.2015 After having raised €100m in its stock market debut, MDx company Biocartis has gained 13 percent on its first trading day.

R&DFranceUKSweden

24.04.2015 AstraZeneca has boosted its oncology portfolio by signing a US$1.275bn agreement with Innate Pharma. The companies plan to further the development of Innate’s tumour-targeting antibody.

PoliticsEU

22.04.2015 A legislative proposal by the European Commission is set to renationalise market authorisation of genetically modified crops.

FinancingUK

21.04.2015 Ahead of its listing on the London Stock Exchange, Woodford’s Patient Capital Trust has raised a record sum of €1.1bn. The fund met with immense interest by investors.

Swiss Biotech DaySwitzerland

16.04.2015 The Swiss biotech industry can look back on 2014 as a good year, but political uncertainties do remain. This was one of the topics discussed during the Swiss Biotech Day in Basel, which attracted more than 400 participants.

EventEUFrance

16.04.2015 The changing landscape in healthcare was just one of the hotly discussed topics of the 27th Annual EuroMeeting of the international association DIA.

R&DBelgium

14.04.2015 Belgian Thrombogenics NV has launched a new oncology company with Gent-based life sciences institute VIB. The new venture will develop an antibody for the treatment of a fast-growing brain tumour that affects children and adolescents.

Events

All Events

Partner-Events

München

BioVaria 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CYTOS1.32 CHF30.69%
  • WILEX5.08 EUR17.32%
  • SYNGENTA339.90 CHF8.11%

FLOP

  • THERAMETRICS0.07 CHF-12.50%
  • MEDIGENE10.26 EUR-6.39%
  • MOLOGEN4.85 EUR-1.82%

TOP

  • 4SC5.20 EUR306.2%
  • WILEX5.08 EUR77.6%
  • PAION2.86 EUR21.7%

FLOP

  • BIOTEST71.20 EUR-26.7%
  • THERAMETRICS0.07 CHF-22.2%
  • MEDIGENE10.26 EUR-16.8%

TOP

  • SANTHERA98.00 CHF2362.3%
  • CYTOS1.32 CHF500.0%
  • WILEX5.08 EUR483.9%

FLOP

  • MOLOGEN4.85 EUR-56.0%
  • THERAMETRICS0.07 CHF-30.0%
  • BIOFRONTERA2.30 EUR-27.7%

No liability assumed, Date: 04.05.2015